# Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular AMD

> **NCT04058535** · PHASE1 · COMPLETED · sponsor: **Alteogen, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **BIOLOGICAL:** Eylea
- **BIOLOGICAL:** ALT-L9

## Key facts

- **NCT ID:** NCT04058535
- **Lead sponsor:** Alteogen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-05
- **Primary completion:** 2020-12-22
- **Final completion:** 2020-12-22
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2022-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04058535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04058535, "Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular AMD". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04058535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*